New imaging agent could sharpen lung cancer detection
NCT ID NCT07007325
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial will test a new radioactive tracer called [68Ga]Ga-PentixaFor in 15 people with metastatic small cell lung cancer. The goal is to see if this PET-CT scan can find tumors as well as the standard FDG PET-CT scan, both at diagnosis and when the disease gets worse. If it works, it may offer a more precise way to image this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[68Ga]Ga-PentixaFor (a radioactive tracer for PET-CT imaging)
What this could lead to
If successful, this could lead to a more accurate imaging method for detecting small cell lung cancer spread, helping doctors choose better treatments.
What could go wrong
This is a very early, small pilot study with only 15 participants. The new tracer may not detect tumors as well as the standard scan, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA (SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU d'Angers
Angers, 49100, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de cancérologie de l'ouest
Angers, 49055, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de cancérologie de l'ouest
Saint-Herblain, 44805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••